Article Text

Download PDFPDF

1159 BRCA-mutation-associated fallopian tube carcinoma
  1. V Benito1,
  2. C Molo2,
  3. P Garcia3 and
  4. A Lubrano4
  1. 1Vithas Las Palmas, Gynecology Oncology, Las Palmas de Gran Canaria, Spain
  2. 2Vithas Las Palmas, Gynecology and Obstetrics, Las Palmas de Gran Canaria, Spain
  3. 3Eurofins Megalab Canarias, Pathology, Las Palmas de Gran Canaria, Spain
  4. 4C.H.U. Insular-Materno Infantil, Gynecology and Obstetrics, Las Palmas de Gran Canaria, Spain


Introduction/Background*Fallopian tube carcinoma is a very rare tumor, comprising less than 1% of all gynecologic cancers and found primarily in postmenopausal women. Women with fallopian tube carcinoma are reported to have a higher frequency of inherited BRCA mutations than those with ovarian carcinoma or primary peritoneal carcinoma, approximately 30% of women with fallopian tube cancer have a mutation in BRCA1 or BRCA2. Described risk factors for BRCA mutations in these patients, are younger age (under 60) and women with a family history of breast or ovarian cancer.

Methodology The patients‘ clinical, pathological, and imaging data are presented. Likewise, the most relevant surgical videos are also presented.

Result(s)*We describe the case of a 58-year-old nulliparous patient with a family history of ovarian cancer who underwent surgery for suspected ovarian cancer with carcinomatosis. Complete debulking surgery was achieved after pelvic peritonectomy, total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, right diaphragmatic peritonectomy and exeresis of several paraaortic enlarged lymph nodes. Histological examination showed the presence of a high-grade serous fallopian tube cancer, FIGO stage IIIB, TNM pT3b N0 M0. Mutational analysis confirmed the presence of a deleterious mutation in BRCA-1. She underwent platinum-based chemotherapy and maintanence therapy with olaparib. Currently, 3 years after treatment, she is alive without evidence of disease.

Conclusion*Given the high frequency of BRCA mutation, all patients diagnosed with invasive fallopian tube cancer should be considered candidates for genetic testing. Likewise, patients with germline BRCA1 gene mutations in whom a prophylactic oophorectomy is performed, removal of fallopian tubes should be strongly considered.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.